Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Average Price Target of $22.29

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has earned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $22.29.

ARCT has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. Citigroup upgraded shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $8.00 to $20.00 in a research report on Thursday, September 24th. Zacks Research raised shares of Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Leerink Partners raised their price objective on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Finally, BTIG Research dropped their price objective on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, September 24th.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $11.03 on Friday. The business has a 50 day simple moving average of $13.61 and a 200 day simple moving average of $8.99. The company has a market capitalization of $313.47 million, a PE ratio of -3.33 and a beta of 2.48. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $17.96.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. The firm had revenue of $2.96 million for the quarter, compared to analysts’ expectations of $3.11 million. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. Equities analysts anticipate that Arcturus Therapeutics will post -3.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently bought and sold shares of the business. Versant Capital Management Inc grew its holdings in shares of Arcturus Therapeutics by 648.6% during the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 2,627 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Arcturus Therapeutics in the second quarter valued at $80,000. Diversify Advisory Services LLC acquired a new stake in shares of Arcturus Therapeutics in the second quarter valued at $91,000. ADAR1 Capital Management LLC bought a new position in shares of Arcturus Therapeutics in the first quarter valued at about $116,000. Finally, Corient Private Wealth LP bought a new position in shares of Arcturus Therapeutics in the second quarter valued at about $117,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.